Appendix 4C Quarterly Report Quarter ended 30 September 2014
Special Meeting of Stockholders - Access for Participants by Webcast and Conference Call
Application for Listing on NASDAQ Capital Market
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE